Days after getting back-to-back approvals from the United Kingdom (UK) and Bahrain health regulatory bodies for the emergency use of its coronavirus vaccine, Pfizer Inc CEO Albert Bourla is now “not certain” if the company-made vaccine to prevent the Covid-19 can actually stop the transmission of the infection. The basic.
The doubt whether Pfizer’s Covid-19 vaccine candidate, with 95 per cent efficacy against Covid-19 vaccine, does prevent its transmission comes as the UK gets ready to roll-out the first batch of 800,000 doses of the coronavirus vaccine. Britain’s business minister Alok Sharma is confident the first batch of 800,000 doses of Pfizer’s coronavirus vaccine would be in place to begin roll-out next week.
However, during an interview with NBC’s Lestor Holt, Pfizer CEO, when asked whether a person can still transmit the virus after vaccination, said he was “not certain”. “I think this is something that needs to be examined. We are not certain about that right now with what we know,” he was quoted as saying.
According to a report, researchers not associated with this coronavirus vaccine’s development, have highlighted how the company’s trials did not assess whether the vaccine affects how the virus spreads. It raises the possibility that vaccinated people could still pass the disease to others.
Meanwhile, Britain hopes that millions of doses of the Pfizer/BioNTech Covid-19 vaccine will be delivered by the end of the year but the total will depend on how quickly it can be manufactured.
Britain approved Pfizer Inc’s coronavirus vaccine on Wednesday, jumping ahead of the rest of the world in the race to begin the most crucial mass inoculation programme in history.
Bahrain, too, has granted the emergency use authorisation (EUA) for Pfizer’s Covid-19 vaccine. Prior to this, Bahrain had authorised a Chinese experimental Covid-19 vaccine made by Sinopharm for emergency use.
According to a report in PTI, Pfizer India has become the first pharmaceutical firm to seek from the Drugs Controller General of India (DCGI) an emergency use authorisation for its Covid-19 vaccine in the country.
The firm, in its application submitted to the drug regulator, has sought permission to import the vaccine for sale and distribution in the country, besides waiver of clinical trials on Indian population in accordance with the special provisions under the New Drugs and Clinical Trials Rules, 2019, PTI quoted its sources as saying.